US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

iShares MSCI Pacific ex Japan ETF

51.38

-0.5850-1.13%

Volume:90.34K

Turnover:4.65M

Market Cap:1.83B

PE:11.89

High:51.59

Open:51.53

Low:51.36

Close:51.96

52wk High:51.99

52wk Low:38.44

Shares:35.70M

Float Shares:35.70M

Volume Ratio:0.47

T/O Rate:0.25%

Dividend:1.83

Dividend Rate:3.56%

EPS(TTM):4.32

EPS(LYR):6.18

ROE:9.62%

ROA:2.24%

PB:0.96

PE(LYR):8.31

Loading ...

Overview Company News Filings

Concept

ESG ETF-MSCI-0.63%

Capital Flow

Inflow:

Outflow:

News

Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update

FDA Accelerated Pathway Feedback on Bitopertin Might Change the Case for Investing in Disc Medicine (IRON)

Simply Wall St.

CLINUVEL Expands SCENESSE® Use to Youngest EPP Patient

Promising Developments at Disc Medicine: NDA Filing and Phase III Trial for Bitopertin in EPP

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/EPP"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EPP\",,,,,undefined,":{"symbol":"EPP","market":"US","secType":"STK","nameCN":"iShares MSCI Pacific ex Japan ETF","latestPrice":51.375,"timestamp":1756149982461,"preClose":51.96,"halted":0,"volume":90335,"delay":0,"floatShares":35700000,"shares":35700000,"eps":4.320112,"marketStatus":"Trading","change":-0.585,"latestTime":"08-25 15:26:41 EDT","open":51.53,"high":51.59,"low":51.36,"amount":4652792.52263,"amplitude":0.004426,"askPrice":51.38,"askSize":300,"bidPrice":51.37,"bidSize":242,"shortable":3,"etf":1,"ttmEps":4.320112,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1756152000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":51.96,"sharesOutstanding":35700000,"nav":51.96095,"aum":1855005915,"dividendRate":0.03562,"bidAskSpread":0.000265,"postHourTrading":{"tag":"盘后","latestPrice":51.96,"preClose":51.96,"latestTime":"16:10 EDT","volume":10,"amount":519.42,"timestamp":1755893404393},"volumeRatio":0.469484,"impliedVol":0.112,"impliedVolPercentile":0.844},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EPP\",,,,,undefined,":{"symbol":"EPP","floatShares":35700000,"roa":"2.24%","roe":"9.62%","lyrEps":6.184397,"volumeRatio":0.469484,"shares":35700000,"dividePrice":1.83,"high":51.59,"amplitude":0.004426,"preClose":51.96,"low":51.36,"week52Low":38.44,"pbRate":"0.96","psRate":"23.18","week52High":51.99,"institutionHeld":0,"latestPrice":51.375,"committee":-0.107011,"eps":4.320112,"divideRate":0.03562,"volume":90335,"delay":0,"ttmEps":4.320112,"open":51.53,"prevYearClose":43.81,"prevWeekClose":51.96,"prevMonthClose":49.34,"prevQuarterClose":49.37,"fiveDayClose":51.01,"twentyDayClose":50.04,"sixtyDayClose":48.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EPP\",params:#limit:5,,,undefined,":[{"date":"2025-06-16","symbol":"EPP","amount":0.858764,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"亚太地区（除日本）ETF-iShares MSCI","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"EPP","amount":0.96746,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"亚太地区（除日本）ETF-iShares MSCI","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"EPP","amount":0.70131,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"亚太地区（除日本）ETF-iShares MSCI","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"},{"date":"2023-12-20","symbol":"EPP","amount":0.966028,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"亚太地区（除日本）ETF-iShares MSCI","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"EPP","amount":0.814552,"announcedDate":"2023-06-06","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"亚太地区（除日本）ETF-iShares MSCI","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EPP\",market:\"US\",,,undefined,":[{"executeDate":"2015-12-21","recordDate":"2015-12-23","paymentDate":"2015-12-28","value":0.927279,"currency":"USD"},{"executeDate":"2016-06-22","recordDate":"2016-06-24","paymentDate":"2016-06-28","value":0.661333,"currency":"USD"},{"executeDate":"2016-12-21","recordDate":"2016-12-23","paymentDate":"2016-12-28","value":0.90607,"currency":"USD"},{"executeDate":"2017-06-20","recordDate":"2017-06-22","paymentDate":"2017-06-26","value":0.756156,"currency":"USD"},{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-25","value":0.867553,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EPP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EPP\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2557080565","title":"Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2557080565","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557080565?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:30","pubTimestamp":1754569800,"startTime":"0","endTime":"0","summary":"Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in October 2025, supported by successful pre-NDA meetingExpect initial data from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/07/3129271/0/en/Disc-Medicine-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPP","BK4139","IRON","BK4582"],"gpt_icon":0},{"id":"2555204490","title":"FDA Accelerated Pathway Feedback on Bitopertin Might Change the Case for Investing in Disc Medicine (IRON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2555204490","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555204490?lang=en_us&edition=fundamental","pubTime":"2025-07-30 22:56","pubTimestamp":1753887393,"startTime":"0","endTime":"0","summary":"Earlier this month, Disc Medicine reported positive feedback from the U.S. FDA regarding its planned New Drug Application submission for bitopertin as a potential treatment for erythropoietic protoporphyria (EPP), targeting an October 2025 filing under the accelerated approval pathway.\nThis milestone highlights bitopertin’s potential to address a significant unmet need for EPP patients, who currently have extremely limited disease-modifying treatment options.\nWe'll assess how this regulatory...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/fda-accelerated-pathway-feedback-on-bitopertin-might-change","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EPP","BK4139","IRON","BK4582"],"gpt_icon":0},{"id":"2543525428","title":"CLINUVEL Expands SCENESSE® Use to Youngest EPP Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2543525428","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543525428?lang=en_us&edition=fundamental","pubTime":"2025-06-13 07:40","pubTimestamp":1749771635,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals ( ($AU:CUV) ) has provided an update. CLINUVEL announced the successful administration of SCENESSE® to a 9-year-old girl w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/clinuvel-expands-scenesse-use-to-youngest-epp-patient?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/clinuvel-expands-scenesse-use-to-youngest-epp-patient?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4582","EPP"],"gpt_icon":0},{"id":"2533775968","title":"Promising Developments at Disc Medicine: NDA Filing and Phase III Trial for Bitopertin in EPP","url":"https://stock-news.laohu8.com/highlight/detail?id=2533775968","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533775968?lang=en_us&edition=fundamental","pubTime":"2025-05-08 03:06","pubTimestamp":1746644761,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tara Bancroft has maintained their bullish stance on IRON stock, giving a Buy rating today. Tara Bancroft’s rating is based on sev...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-at-disc-medicine-nda-filing-and-phase-iii-trial-for-bitopertin-in-epp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-at-disc-medicine-nda-filing-and-phase-iii-trial-for-bitopertin-in-epp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4582","III","EPP","BK4134","IRON"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/EPP\",params:#limit:6,delay:false,,,undefined,":[{"market":"US","name":"ESG ETF-MSCI","bkCode":"BK4582","id":"package_us_concept_esgetfmsci","changeRate":-0.006258}]}}